Previous Close | 0.0300 |
Open | 0.0250 |
Bid | 0.0250 x N/A |
Ask | 0.0300 x N/A |
Day's Range | 0.0250 - 0.0250 |
52 Week Range | 0.0250 - 0.3000 |
Volume | |
Avg. Volume | 16,155 |
Market Cap | 12.606M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0220 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jan 22, 2018 |
1y Target Est | N/A |
LOVE Pharma Inc. ("LOVE" and or "the Company") (CSE:LUV)(FSE:G1Q0)announced it intends to proceed with a consolidation of its common shares (each, a "Share") on the basis of ten (10) pre-consolidation Shares for one (1) post-consolidation Share (the "Consolidation").
VANCOUVER, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) continues with its plans to develop a portfolio of innovative products encompassing transdermal drug delivery applications. On October 11th, LOVE Pharma signed a nonbinding Letter of Intent to acquire 100% of Naltrexone Therapeutics, bringing significant IP related to the transdermal delivery of FDA approved Naltrexone, an opioid antagonist, primarily used to manage alcohol and or opioid use disorder